Karyopharm's innovative therapy Xpovio (selinexor) Phase 2b clinical trial yields positive results

recently, Karyopharm Therapeuticscompany(http://announced positive results from theof its innovative clinical(http:// for the treatment of recurrent/incurable multiple myelomastudy was published in the New England Journal of Medicine (NEJM)Xpovio
Xpovio is a "first-in-class" oral protodosis selective nuclear output inhibitor that binds to the nucleoid protein XPO1 and inhibits its function, thus blocking the nuclear output of tumor suppressors, growth-regulating proteins, and anti-inflammatory proteins, causing it to accumulate in the nucleus, restart or enhance its tumor inhibition functionJuly 2019, Xpovio received accelerated approval from the u.SFDA(http://This innovative therapy can be combined with dexamethasone to treat patients with recurrent/incurable multiple myelomaPhase 2b clinical trials recruited 122 patients with stage 3 recurrent/refractory multiple myeloma who received an average of seven treatments in the previous period and developed rapidlypatients received Xpovio and dexamethasone combined administration, 39% (48) of the condition stabilized, with a total remission rate of 26%, with a median total survival of 8.6 months